Association between the 2008–09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring–Summer 2009: Four Observational Studies from Canada

English version České info

Background:
In late spring 2009, concern was raised in Canada that prior vaccination with the 2008–09 trivalent inactivated influenza vaccine (TIV) was associated with increased risk of pandemic influenza A (H1N1) (pH1N1) illness. Several epidemiologic investigations were conducted through the summer to assess this putative association.

Methods and Findings:
Studies included: (1) test-negative case-control design based on Canada's sentinel vaccine effectiveness monitoring system in British Columbia, Alberta, Ontario, and Quebec; (2) conventional case-control design using population controls in Quebec; (3) test-negative case-control design in Ontario; and (4) prospective household transmission (cohort) study in Quebec. Logistic regression was used to estimate odds ratios for TIV effect on community- or hospital-based laboratory-confirmed seasonal or pH1N1 influenza cases compared to controls with restriction, stratification, and adjustment for covariates including combinations of age, sex, comorbidity, timeliness of medical visit, prior physician visits, and/or health care worker (HCW) status. For the prospective study risk ratios were computed. Based on the sentinel study of 672 cases and 857 controls, 2008–09 TIV was associated with statistically significant protection against seasonal influenza (odds ratio 0.44, 95% CI 0.33–0.59). In contrast, estimates from the sentinel and three other observational studies, involving a total of 1,226 laboratory-confirmed pH1N1 cases and 1,505 controls, indicated that prior receipt of 2008–09 TIV was associated with increased risk of medically attended pH1N1 illness during the spring–summer 2009, with estimated risk or odds ratios ranging from 1.4 to 2.5. Risk of pH1N1 hospitalization was not further increased among vaccinated people when comparing hospitalized to community cases.

Conclusions:
Prior receipt of 2008–09 TIV was associated with increased risk of medically attended pH1N1 illness during the spring–summer 2009 in Canada. The occurrence of bias (selection, information) or confounding cannot be ruled out. Further experimental and epidemiological assessment is warranted. Possible biological mechanisms and immunoepidemiologic implications are considered.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Association between the 2008–09 Seasonal Influenza Vaccine and Pandemic H1N1 Illness during Spring–Summer 2009: Four Observational Studies from Canada. PLoS Med 7(4): e32767. doi:10.1371/journal.pmed.1000258
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000258

Souhrn

Zdroje

1. CDC 2009 Swine influenza A (H1N1) infection in two children - Southern California, March–April 2009. MMWR Morb Mortal Wkly Rep 58 400 402

2. Novel swine-origin influenza A(H1N1) virus investigation team 2009 Emergence of a novel swine-origin influenza A (H1N1) virus in humans. New Engl J Med 361 1 10

3. ChowellG

BertozziSM

ColcheroMA

Lopez-GatellH

Alpuche-ArandaC

2009 Severe respiratory disease concurrent with the circulation of H1N1 influenza. New Engl J Med 361 674 79

4. Perez-PadillaR

de la Rosa-ZamboniD

Ponce de LeonS

HernandezM

Quinones-FalconiF

2009 Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. New Engl J Med 361 680 89

5. WHO 11 June 2009 Transcript of statement by Margaret Chan, Director-General of the World Health Organization. Available: http://www.who.int/mediacentre/influenzaAH1N1_presstranscript_20090611.pdf. Accessed 26 February 2010

6. KatzJ

HancockK

VeguillaV

ZhongW

SunH

2009 Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 58 521 524

7. WHO 2009 WHO pandemic (H1N1) briefing note 9: Preparing for the second wave: lessons from current outbreaks. Available at: http://www.who.int/csr/disease/swineflu/notes/h1n1_second_wave_20090828/en/index.html. Accessed 26 February 2010

8. National Advisory Committee on Immunization 2008 Statement on influenza vaccination for the 2008–09 season. Can Commun Dis Rep ACS-3 34 1 46

9. JanjuaNZ

SkowronskiDM

HottesTS

OseiW

PetricM

2010 Seasonal influenza vaccine and increased risk of pandemic H1N1 illness: first detection of the association during outbreak investigation in British Columbia, Canada. 13th Annual Conference on Vaccine Research, Bethesda, MD, 27 April 2010. Abstract # 130

10. SkowronskiDM

GilbertM

TweedSA

PetricM

LiY

2005 Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004–05. Can Commun Dis Rep 31 181 192

11. SkowronskiDM

MasaroC

KwindtTL

MakA

PetricM

2007 Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. Vaccine 25 2842 2851

12. SkowronskiDM

De SerresG

DickinsonJ

PetricM

MakA

2009 Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006–07. J Infect Dis 199 168 179

13. RodriguesL

KirkwoodBR

1990 Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol 19 205 13

14. OrensteinWA

BernierRH

DonderoTJ

HinmanAR

MarksJS

1985 Field evaluation of vaccine efficacy. Bull WHO 63 1055 1068

15. Statistics Canada 2005 Canadian Community Health Survey (Cycle 3.1). Ottawa, ON

16. Statistics Canada 2009 Influenza Immunization Coverage by Province and age 2007–08. In: Table 105-0502. Health indicator profile, annual estimates, by age group and sex, Canada, provinces, territories, health regions (2007 boundaries) and peer groups, occasional (1209600 series). Available: http://cansim2.statcan.gc.ca/cgi-win/cnsmcgi.pgm?Lang=E&RootDir=CII/&Array_Pick=1&ArrayId=105-0502&C2DB=PRD&ResultTemplate=CII%2FCII

17. ItohY

ShinyaK

KisoM

WatanabeT

SakodaY

2009 In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460 1021 1025

18. HancockK

VeguillaV

XiuhuaL

ZhongW

ButlerEN

2009 Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. 361 1 8

19. HakE

VerheijThJM

GrobbeeDE

NicholKL

2002 Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Community Health 56 951 955

20. JacksonLA

JacksonML

NelsonJC

NeuzilKM

WeissNS

2006 Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35 337 344

21. JacksonLA

NelsonJC

BensonP

NeuzilKM

ReidRJ

2006 Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 35 345 352

22. KellyH

GrantK

2009 Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Eurosurveillance 14. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19288. Accessed 26 February 2010

23. Garcia-GarciaL

Valdespino-GomezJL

Lazcano-PonceE

Jimenez-CoronaA

Higuera-IglesiasA

2009 Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 339: b3928. Available: http://www.bmj.com/cgi/content/full/339/oct06_2/b3928 Accessed 26 February 2010

24. Echevarria-ZunoS

Mejia-ArangureJM

Mar-ObesoAJ

Grajales-MunizC

Robles-PerezE

2009 Infection and deaths from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 374 2072 2079

25. GargiulloP

ShayD

KatzJ

BramleyA

NowellM

2009 Effectiveness of 2008–09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May–June 2009. MMWR Morb Mortal Wkly Rep 58 1241 1245

26. IulianoAD

ReedC

GuhA

DesaiM

KuttyP

2009 Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April–May 2009. Clin Infect Dis 49 1811 1820

27. Crum-CianfloneNF

BlairPJ

FaixD

ArnoldJ

EcholsS

2009 Clinical and epidemiologic characteristics of an outbreak of novel H1N1 (swine origin) influenza A virus among United States military beneficiaries. Clin Infect Dis 49 1801 1810

28. JanjuaNZ

SkowronskiDM

HottesTS

De SerresG

CrowcroftNS

2009 Seasonal vaccine and H1N1. Selection bias explains seasonal vaccine's protection. BMJ 339 b4972

29. JanjuaNZ

SkowronskiDM

HottesTS

De SerresG

CrowcroftNS

2010 Bias and seasonal vaccine effectiveness against pandemic A/H1N1. Lancet 375 801 802

30. HoskinsTW

DaviesJR

SmithAJ

AlchinA

MillerCL

1976 Influenza at Christ's Hospital: March, 1974. Lancet 1 105 108

31. BodewesR

KreijtzJHCM

BaasC

Geelhoed-MierasMM

de MutsertG

2009 Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 Virus. PLoS ONE 4 e5538 doi:10.1371/journal.pone.0005538

32. BodewesR

KreijtzJHCM

RimmelzwaanGF

2009 Yearly influenza vaccinations: a double-edged sword? Lancet Infect Dis 9 784 788

33. PaleseP

2004 Influenza: new and old threats. Nat Med 10 S82 7

34. WebsterRG

1966 Original antigenic sin in ferrets: the response to sequential infections with influenza viruses. J Immunol 97 177 183

35. de St. FazekasG

WebsterRG

1966 Disquisitions on original antigenic sin, II: proof in lower creatures. J Exp Med 124 347 361

36. de St. FazekasG

WebsterRG

1966 Disquisitions of original antigenic sin, I: evidence in man. J Exp Med 124 331 345

37. KimJH

SkountzouI

CompansR

JacobJ

2009 Original antigenic sin responses to influenza viruses. J Immunol 183 3294 3301

38. StephensonJR

2005 Understanding dengue pathogenesis: implications for vaccine design. Bull WHO 83 308 314

39. SauterP

HoberD

2009 Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect 11 443 451

40. TakadaA

KawaokaY

2003 Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13 387 398

41. GotoffR

TamuraM

JanusJ

ThompsonJ

WrightP

1994 Primary influenza A virus infection induces cross-reactive antibodies that enhance uptake of virus into Fc receptor-bearing cells. J Infect Dis 169 200 203

42. OchiaiH

KurokawaM

KurokiY

NiwayamaS

1990 Infection enhancement of influenza A H1 subtype viruses in macrophage-like P388D1 cells by cross-reactive antibodies. J Med Virol 30 258 265

43. OchiaiH

KurokawaM

HayashiK

NiwayamaS

1988 Antibody-mediated growth of influenza A NWS virus in macrophagelike cell line P388D1. J Virol 62 20 26

44. OchiaiH

KurokawaM

MatsuiS

YamamotoT

KurokiY

1992 Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody. J Med Virol 36 217 221

45. VincentAL

LagerKM

JankeBH

GramerMR

RichtJA

2008 Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine. Vet Microbiol 126 310 323

46. KitikoonP

NilubolD

EricksonBJ

JankeBH

HooverTC

2006 The immune response and maternal antibody interference to a heterologous H1N1 swine influenza virus infection following vaccination. Vet Immunol Immunopathol 112 117 128

47. KobingerGP

MeunierI

PatelA

PilletS

GreenJ

2010 Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus. J Infect Dis 201 1000 1006

48. GreenbaumJA

KotturiMF

KimY

OseroffC

VaughanK

2009 Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 106 20365 20370 Available: http://www.pnas.org/content/106/48/20365. Accessed 26 February 2010

49. World Health Organization 2010 Pandemic (H1N1) 2009 – update 89. Weekly virological surveillance update. Available at: http://www.who.int/csr/disease/swineflu/laboratory26_02_2010/en/index.html. Accessed 26 February 2010

50. World Health Organization 2010 Recommended composition of influenza vaccines for use in the 2010 southern hemisphere influenza season. Available at: http://www.who.int/csr/disease/influenza/recommendations2010south/en/index.html. Accessed 26 February 2010

51. World Health Organization 2010 Recommended viruses for influenza vaccines for use in the 2010–2011 northern hemisphere influenza season. Available at: http://www.who.int/csr/disease/influenza/recommendations2010_11north/en/index.html. Accessed 26 February 2010